UBS Group’s Protara Therapeutics TARA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Shares
Change %
Capital Flow Portfolio Weight Portfolio Position
2025
Q2
$3.44M Buy
1,135,767
+499,093
+78% +$1.51M ﹤0.01% 3374
2025
Q1
$2.71M Buy
636,674
+487,266
+326% +$2.08M ﹤0.01% 3477
2024
Q4
$789K Buy
149,408
+141,990
+1,914% +$750K ﹤0.01% 4383
2024
Q3
$13.6K Buy
+7,418
New +$13.6K ﹤0.01% 6371
2024
Q2
Sell
-3,725
Closed -$14.9K 8760
2024
Q1
$14.9K Buy
3,725
+2,809
+307% +$11.3K ﹤0.01% 5879
2023
Q4
$1.72K Buy
916
+795
+657% +$1.49K ﹤0.01% 7024
2023
Q3
$202 Buy
+121
New +$202 ﹤0.01% 7561
2023
Q2
Sell
-971
Closed -$3.04K 8399
2023
Q1
$3.04K Sell
971
-1,329
-58% -$4.16K ﹤0.01% 7294
2022
Q4
$6.16K Buy
2,300
+2,061
+862% +$5.52K ﹤0.01% 7877
2022
Q3
$1K Sell
239
-1,032
-81% -$4.32K ﹤0.01% 8928
2022
Q2
$4K Buy
1,271
+697
+121% +$2.19K ﹤0.01% 8084
2022
Q1
$3K Buy
+574
New +$3K ﹤0.01% 8426
2021
Q3
Sell
-99
Closed -$1K 8766
2021
Q2
$1K Sell
99
-1,338
-93% -$13.5K ﹤0.01% 8076
2021
Q1
$23K Buy
1,437
+776
+117% +$12.4K ﹤0.01% 6229
2020
Q4
$16K Buy
661
+523
+379% +$12.7K ﹤0.01% 6099
2020
Q3
$2K Sell
138
-532
-79% -$7.71K ﹤0.01% 6805
2020
Q2
$20K Buy
670
+298
+80% +$8.9K ﹤0.01% 5719
2020
Q1
$9K Buy
372
+170
+84% +$4.11K ﹤0.01% 6100
2019
Q4
$132K Sell
202
-598
-75% -$391K ﹤0.01% 4840
2019
Q3
$8K Buy
+800
New +$8K ﹤0.01% 6326
2019
Q1
Sell
-30
Closed -$3K 7113
2018
Q4
$3K Buy
+30
New +$3K ﹤0.01% 6799
2018
Q3
Sell
-55
Closed -$5K 7171
2018
Q2
$5K Buy
55
+52
+1,733% +$4.73K ﹤0.01% 6551
2018
Q1
$0 Sell
3
-145
-98% ﹤0.01% 7062
2017
Q4
$11K Buy
148
+145
+4,833% +$10.8K ﹤0.01% 5996
2017
Q3
$0 Hold
3
﹤0.01% 6900
2017
Q2
$0 Hold
3
﹤0.01% 6854
2017
Q1
$0 Sell
3
-67
-96% ﹤0.01% 6814
2016
Q4
$5K Buy
70
+62
+775% +$4.43K ﹤0.01% 6275
2016
Q3
$3K Buy
+8
New +$3K ﹤0.01% 6361
2016
Q1
Sell
-28
Closed -$17K 6862
2015
Q4
$17K Buy
28
+21
+300% +$12.8K ﹤0.01% 5687
2015
Q3
$4K Sell
7
-7
-50% -$4K ﹤0.01% 6383
2015
Q2
$10K Buy
+14
New +$10K ﹤0.01% 5979
2015
Q1
Sell
-28
Closed -$12K 6792
2014
Q4
$12K Buy
+28
New +$12K ﹤0.01% 5908